Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Organon's natural estrogen contraceptive enters phase III trials

May 18, 2007

Luitpold seeks FDA approval for iron replacement therapy

May 17, 2007

Novel animation depicting GLP-1 and DPP IV as therapeutic targets for diabetes and obesity

May 17, 2007

VGX Pharmaceuticals and Baylor College of Medicine enter GHRH license agreement

May 16, 2007

Novel treatment options for obesity and other metabolic disorders reported in recent patents

May 16, 2007

FDA approves Fosamax Plus D with higher vitamin D content

May 15, 2007

Recent Chugai and sanofi-aventis patents describe new treatment options for diabetes

May 15, 2007

GlaxoSmithKline returns rights to Futura for MED-2002 for ED

May 15, 2007

Enrollment completed in final phase II trial for Testosterone MD-Lotion

May 14, 2007

Dosing completes in two phase IIa obesity trials of oleoyl-estrone

May 14, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...